Shots:
- The P-ll/lll trial involves assessing of REGN-COV2 (8gm/2.4gm) + SOC vs PBO + SOC in 524 patients with mild-to-moderate COVID-19 in an outpatient setting
- The study met its 1EPs & 2EPs demonstrating a reduction in viral load and patient medical visits. Moreover, Regeneron is reviewing potential changes to dosing in the ongoing outpatient clinical trial given the current limited supply of REGN-COV2
- REGN-COV2 is a combination of two mAbs (REGN10933 + REGN10987), designed specifically to block the infectivity of SARS-CoV-2. Additionally, Regeneron has shared results with the US FDA, which is reviewing a EUA submission for the REGN-COV2 low dose in adults with mild-to-moderate COVID-19 who are at high risk for poor outcomes
Click here to read full press release/ article | Ref: PRNewswire | Image: MediCircle
The post Regeneron Reports Results of REGN-COV2 in P-ll/lll Study in Patients with COVID-19 in Outpatient Setting first appeared on PharmaShots.
